Märta Segerdahl, Chief Medical Officer, Asarina Pharma
Asarina Pharma’s current Phase II Study is the first in 10 yrs to develop a new, preventative treatment for Menstrual Migraine. As a prophylactic, the new treatment, Sepranolone, has been designed not just to treat Menstrual Migraine symptoms – but to prevent them from occurring.
TARGET SITES: Finland, Sweden
NUMBER OF PATIENTS: 78-90
AGE OF PATIENTS: 18-45 years
CRO: SCRO (Scandinavian CRO) based in Uppsala Sweden
TREATMENT: prophylactic neurosteroid Sepranolone
ADMINISTRATION: pre-filled syringes for self-administration
TIMELINE: full patient enrolment reached September 2020, topline results expected Q2 2021
The American Migraine Foundation
Why is it so important that Sepranolone is preventive? Menstrual Migraine attacks are often resistant to standard, symptomatic treatments. For example: A woman with two or three migraine attacks a month on top of her menstrual migraine attacks, will typically find that whilst her standard preventive treatment may work successfully for her non-menstrual attacks—it won’t have any effect on her Menstrual Migraine attacks. With often longer bouts of pain the temptation with Menstrual Migraine can be to take symptomatic therapies in large amounts over long periods, causing concern over how much treatment to take, how long it can be taken for, relapse of symptoms over several consecutive days and associated menstrual disorder. As a prophylactic cure, Sepranolone avoids these concerns. New prophylactic therapies represent a new paradigm shift in migraine treatments. Sepranolone is unique amongst them. None of the clinical studies for recently launched new antibodies against migraine, for example, have specifically analyzed their effect in women suffering from Menstrual Migraine. Sepranolone offers powerful benefits to women managing menstrual migraine over a lifetime.